GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Hosted on MSN10mon
Diabetes medication appears to slow progress of Parkinson’s disease in French-backed trial
A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson’s disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others ...
pharmaphorum6d
Trial finds benefit for GLP-1 agonist in Parkinson’s
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...
pharmaphorum8y
Sanofi GLP-1 finally approved in US
Sanofi has finally had is type 2 diabetes drug, lixisenatide, approved in the US, creating further competition against Novo Nordisk’s market leading Victoza. The French pharma withdrew its US ...